Ovid Therapeutics Hits New 52-Week High of $2.50, Marking Major Milestone

Ovid Therapeutics, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 2.50 on March 18, 2026. This achievement marks a notable point in the stock's performance, especially considering its 52-week low was recorded at USD 0.24. Despite the recent uptick, Ovid Therapeutics has experienced a challenging year, with a one-year performance decline of 25.81%, contrasting sharply with the S&P 500's gain of 17.99%. The company's market capitalization stands at USD 254 million, reflecting its microcap status. Financial metrics reveal that Ovid Therapeutics is currently loss-making, with a return on equity of -70.39% and a debt-to-equity ratio of -0.54. The stock does not offer a dividend yield, and its price-to-book ratio is 5.68. As Ovid Therapeutics continues to navigate the complexities of the biotechnology landscape, this recent price milestone highlights the stock's volatility and the broader market dynamics at play.